Literature DB >> 1973827

Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells.

C Dati1, S Antoniotti, D Taverna, I Perroteau, M De Bortoli.   

Abstract

The c-erbB-2 oncogene is thought to play a relevant role in the development and progression of mammary neoplasia. Using the human breast cancer cell lines T47D and MCF7, we found that the arrest of cell growth induced by a steroid-depleted medium was accompanied by a strong increase of c-erbB-2 mRNA and of the c-erbB-2-encoded p185 protein. The treatment of arrested cells with estrogens was found to resume cell proliferation and to inhibit dramatically c-erbB-2 expression at both mRNA and protein level. The regulation of c-erbB-2 expression was remarkably different from that observed for c-myc, which was strongly stimulated by estrogens, and ras, whose expression was unaffected all through the treatments. In addition, in the normal rat mammary gland undergoing development and differentiation during pregnancy and lactation, p185 expression was detected only in the functionally differentiated tissue. Altogether, our data indicate that the expression of c-erbB-2 is repressed during estrogen-induced proliferation and enhanced during growth arrest and/or differentiation of mammary cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973827

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

Review 1.  Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland.

Authors:  N P Bates; H C Hurst
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 2.  Systems approaches to molecular cancer diagnostics.

Authors:  Shuyi Ma; Cory C Funk; Nathan D Price
Journal:  Discov Med       Date:  2010-12       Impact factor: 2.970

3.  Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients.

Authors:  Qi-Xing Tan; Qing-Hong Qin; Wei-Ping Yang; Bin Lian; Chang-Yuan Wei
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells.

Authors:  Mary S Sakla; Nader S Shenouda; Pete J Ansell; Ruth S Macdonald; Dennis B Lubahn
Journal:  Endocrine       Date:  2007-10-02       Impact factor: 3.633

5.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

Review 6.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha.

Authors:  H Kalthoff; C Roeder; J Gieseking; I Humburg; W Schmiegel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

Review 8.  The significance of heregulin in breast cancer tumor progression and drug resistance.

Authors:  R Lupu; M Cardillo; C Cho; L Harris; M Hijazi; C Perez; K Rosenberg; D Yang; C Tang
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

9.  Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification.

Authors:  Alison Millson; Arminda Suli; Leah Hartung; Steve Kunitake; Ann Bennett; Mary C Lowry Nordberg; Wedad Hanna; Carl T Wittwer; Arun Seth; Elaine Lyon
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

10.  Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.

Authors:  M Hauglid Flågeng; L L Haugan Moi; J M Dixon; J Geisler; E A Lien; W R Miller; P E Lønning; G Mellgren
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.